

NOVO NORDISK A S
Form 6-K
January 30, 2013

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

January 30, 2013

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 30 January 2013 – On 9 November 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk has repurchased B shares for an amount of DKK 1.5 billion in the period from 9 November 2012 to 29 January 2013. The programme is now concluded.

Since the announcement as of 21 January 2013, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,250,897		1,180,085,972
21 January 2013	55,000	986.57	54,261,394
22 January 2013	54,733	997.80	54,612,828
23 January 2013	55,000	1,009.14	55,502,541
24 January 2013	55,000	1,008.02	55,440,897
25 January 2013	54,933	1,014.31	55,719,349
28 January 2013	40,000	1,014.99	40,599,576
29 January 2013	3,727	1,013.40	3,776,931
Accumulated under the programme	1,569,290		1,499,999,488

With the transactions stated above, Novo Nordisk owns a total of 18,442,009 treasury shares, corresponding to 3.3% of the share capital. The total amount of shares in the company is 560,000,000 including treasury shares.

Novo Nordisk A/S Novo Allé
Investor Relations 2880 Bagsværd
Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
www.novonordisk.com
CVR no:
24 25 67 90

Company announcement No 7 /
2013

During the 12 month period beginning 2 February 2012 and ending 29 January 2013, Novo Nordisk has repurchased a total of 14,082,750 B shares equal to a transaction value of DKK 11,999,998,799. The DKK 12.0 billion share repurchase programme announced 2 February 2012 is hereby concluded.

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge
Ken Inchausti (US)

+45 4442 3450
+1 609 514 8316

amhg@novonordisk.com
kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen
Frank Daniel Mersebach
Lars Borup Jacobsen
Jannick Lindegaard (US)

+45 4442 4303
+45 4442 0604
+45 3075 3479
+1 609 786 4575

krop@novonordisk.com
fdni@novonordisk.com
lbpj@novonordisk.com
jlis@novonordisk.com

Novo Nordisk A/S Novo Allé
Investor Relations 2880 Bagsværd
Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
www.novonordisk.com
CVR no:
24 25 67 90

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: January 30, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer